Influence of Tumor Vaccines on Graft Versus Tumor Activity and Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation
- 1 January 2002
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (3) , 503-510
Abstract
Powerful immunologically-mediated antitumor efforts can be observed in allogeneic hematopoietic stem cell transplantation. In the absence of specific immune interventions, this graft versus tumor effect is closely associated with graft versus host disease. In the work summarized here, the influence of cellular tumor vaccines on graft versus tumor activity and graft versus host disease is examined in a murine model of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation. The experiments have generated the following conclusions. First, complex cellular vaccines, which include recipient minor histocompatibility antigens, when administered to allogeneic donors generate powerful graft versus tumor effects but also induce unacceptable exacerbations of graft versus host disease. Second, cellular tumor vaccines, which contain recipient minor histocompatibility antigens, can be administered to transplant recipients after transplant without significant exacerbation of GVHD and with retention of clinically significant graft versus tumor effects. Third, immunization of donors with molecularly defined tumor-associated antigens, which are not recipient minor histocompatibility antigens, can be coupled with post-transplant immunization of recipients with cellular vaccines without exacerbation of GVHD.Keywords
This publication has 22 references indexed in Scilit:
- Ganciclovir Chemoablation of Herpes Thymidine Kinase Suicide Gene-Modified Tumors Produces Tumor Necrosis and Induces Systemic Immune ResponsesHuman Gene Therapy, 1998
- Minor histocompatibility antigensCurrent Opinion in Immunology, 1997
- Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.Journal of Clinical Investigation, 1996
- Human minor histocompatibility antigensCurrent Opinion in Immunology, 1996
- Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, ItalyHuman Gene Therapy, 1995
- Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic NeoplasmsNew England Journal of Medicine, 1989
- Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes.Journal of Experimental Medicine, 1987
- Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice.Journal of Experimental Medicine, 1987
- Cytotoxic T cells recognize fragments of the influenza nucleoproteinCell, 1985
- Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.Journal of Experimental Medicine, 1978